← Leaderboards
Jan Chen
Glsynthesis, Inc.
$5,485,624
Attributed
$5,485,624
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2006–09$2M$1.5M$1M$500K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$5,485,624 · 3
By mechanism
R44$5,259,872 · 2
R43$225,752 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Urinary Incontinence”
- Marie G Gantz · Research Triangle Institute$29,345,285
- Sharon L Tennstedt · New England Research Institutes, Inc.$16,847,458
- Linda J Waite · University Of Chicago$12,029,335
- Holly E Richter · University Of Alabama At Birmingham$11,561,493
- Tom F Lue · University Of California San Francisco$10,209,526
- Alison Huang · University Of California, San Francisco$9,835,462
Research focus
Urinary IncontinenceReceptor BindingCalcium Channel BlockersLicensingHepatocyteLaboratoriesDrug DevelopmentClinical TrialsDermalDrug Design /Synthesis /ProductionGrantGuidelinesIn VitroIn VivoAdverse EffectsAnalogAnalytical MethodChemical SynthesisAnesthesia ProceduresBiologicalAnimalsDose-LimitingAge-YearsCollaborations
Grant awards (7)
Novel Drugs to Treat Urinary Incontinence$894,091
R44 · FY2009 · AG · contact PI
Novel Drugs to Treat Urinary Incontinence$794,658
R44 · FY2008 · AG · contact PI
Non-Sedating Atropisomeric Drugs for Atopic Diseases$1,554,089
R44 · FY2007 · GM · contact PI
Non-Sedating Atropisomeric Drugs for Atopic Diseases$1,042,236
R44 · FY2006 · GM · contact PI
Non-Sedating Atropisomeric Drugs for Atopic Disease$225,752
R43 · FY2004 · GM
NOVEL DRUGS TO TREAT URINARY INCONTINENCE$459,046
R44 · FY2001 · AG
NOVEL DRUGS TO TREAT URINARY INCONTINENCE$515,752
R44 · FY2000 · AG